The expression of PD‐L1 in breast cancer is associated with estrogen receptor negativity,
chemoresistance and epithelial‐to‐mesenchymal transition (EMT), all of which are common …

Background Breast cancer stem cells have self-renewal capability and are resistant to
conventional chemotherapy. PD-L1 could promote the expression of stemness markers …

The T-cell inhibitory molecule PD-L1 is expressed on a fraction of breast cancer cells. The
distribution of PD-L1 on the different subpopulations of breast cancer cells is not well …

Objectives: Breast cancer is the most commonly diagnosed cancer, and it is a leading cause
of cancer-related deaths in females worldwide. Triple-negative breast cancer (TNBC) …

Although the role of PD-L1 in suppressing the anti-tumor immune response is extensively
documented, recent discoveries indicate a distinct tumor-intrinsic role for PD-L1 in …

Tumor progression through immune evasion is a major challenge in cancer therapy. Recent
studies revealed that enhanced PD-L1 expression in cancer stem cells is linked to immune …

Purpose To evaluate the association between PD-L1 expression (PD-L1+) and
clinicopathological characteristics and effect on prognosis in primary breast cancer (PBC) …

Early-phase trials targeting the T-cell inhibitory molecule programmed cell death ligand 1
(PD-L1) have shown clinical efficacy in cancer. This study was undertaken to determine …

Triple-negative breast cancers (TNBCs) are characterized by a poor prognosis and lack of
targeted treatments, and thus, new therapeutic strategies are urgently needed. Inhibitors …

The associations between programmed cell death ligand 1 (PD-L1) and the prognosis of
various cancers have always been a research topic of considerable interest. However, the …